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Well-designed randomized trials provide the highest level of scientific evidence to guide
clinical decision making. In chemoradiotherapy of locally advanced squamous cell
carcinoma of the head and neck (SCCHN), data support the use of three cycles of
100 mg/m2 cisplatin given every 3 weeks concurrently with conventionally fractionated
external beam radiotherapy, although a full compliance with all three cycles is reserved
to only about two thirds of initially eligible cases. On an individual patient level, practicing
oncologists have to determine whether the patient is a suitable candidate for this
treatment or whether contraindications exist. In the latter case, an adequate alternative
has to be offered. In this regard, to facilitate triaging of medical information, we reviewed
available publications on this topic and prepared practice-oriented recommendations
for systemic treatment concurrent to definitive and post-operative radiotherapy. Even
if no contraindications for the standard-of-care cisplatin apply, clinicians may opt for
alternative regimens by adjusting the peak dose, cumulative dose, or timing of cisplatin.
Relative contraindications pose the major issue in clinical practice, as very limited data
is available in the literature and final decisions are usually based on an expert opinion
or retrospective cohort studies. In the case of absolute interdiction of cisplatin, several
alternative regimens incorporating carboplatin, 5-fluorouracil, cetuximab, and docetaxel
are available. At the same time, it should be kept in mind that radiotherapy alone
represents a viable option with hyperfractionation being particularly beneficial in the
definitive management of limited nodal disease. Ideally, all treatment propositions should
be discussed within multidisciplinary tumor boards taking into account the patient- and
disease-related characteristics as well as local logistics and reimbursement policies.
Keywords: head and neck cancer, chemoradiotherapy, cisplatin, cetuximab, targeted therapy, immunotherapy,
clinical trials, practice recommendations
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INTRODUCTION
Locoregionally advanced disease is still the most frequent clinical
manifestation in patients with squamous cell carcinoma of the
head and neck (SCCHN). In this setting, chemoradiotherapy
offers an effective non-surgical approach as primary treatment,
or alternatively, it can be delivered with adjuvant intent after
a curative resection (1). Whether being part of bimodality or
trimodality management, chemoradiotherapy usually comes at
the cost of substantial acute and late toxicity, and it has been
subject of numerous clinical trials to establish a treatment
schedule with a reasonable compromise between its tumoricidal
activity on the one hand and dose-limiting side effects on the
other (2). This paper sets out to present the current standard-
of-care chemoradiotherapy regimen in non-nasopharyngeal
mucosal head and neck cancer along with other commonly
used protocols for which a lower level of clinical evidence
applies. Based on this theoretical framework, practice-oriented
recommendations were conceptualized focusing primarily on
systemic treatment. The different treatment options were
categorized by clinical settings (definitive or post-operative)
and by the presence or absence of contraindications to the
standard-of-care treatment (absolute or relative). In addition, to
rate the quality of evidence and strength of recommendations
of each schedule mentioned here, the European Society for
Medical Oncology (ESMO) grading consensus system was
adopted (Table 1) (3). However, precise clinical, radiological, and
pathological criteria used to select cases suitable for definitive
or adjuvant chemoradiotherapy are not covered in this article.
Furthermore, enrolment of patients in clinical research is highly
recommended whenever a well-designed randomized trial opens
for recruitment.
DEFINING THE STANDARD OF CARE
The findings from four large randomized phase III trials
established cisplatin-based chemoradiotherapy as the reference
treatment both in the definitive and adjuvant treatment settings
(3–8). The regimen consists of three infusions of 100 mg/m2
cisplatin given every 3 weeks concurrently with conventionally
fractionated external beam radiotherapy. It represents a cost-
effective, broadly available, and accessible treatment option
(9, 10). The growing interest in de-intensification strategies
investigated primarily in human papillomavirus (HPV)-positive
oropharyngeal cancer has recently been dampened by the results
of two phase III trials confirming the primacy of high-dose
cisplatin against cetuximab (11, 12). Mounting evidence suggests
that HPV-associated oropharyngeal cancer in men should be
regarded as a separate entity with different biology and clearly
a better prognosis (13). In economically developed countries,
the prevalence of HPV-associated oropharyngeal cancer in
men has been sharply increasing over the past three decades
(14). At the same time, these regions have been the major
force of clinical trial recruitment, enhancing their influence in
academic communities (15). Thus, a notion may inadvertently be
acquired that the changing epidemiologic landscape is uniform
worldwide. However, the majority of patients with head and
neck cancer still present with HPV-negative disease in which
outcomes have been unsatisfactory calling for preservation
of a sufficient treatment intensity. At present, HPV status
has no predictive value in locoregionally advanced head and
neck cancer.
Enrolling altogether 842 patients during the 1990s, two of the
aforementioned trials were conducted in the definitive setting
(4, 5). In a Head and Neck Intergroup trial, Adelstein et al.
tested the benefit of chemotherapy as an adjunct to concurrent
radiotherapy in patients with (mainly) unresectable squamous
cell carcinoma of the oral cavity, oropharynx, hypopharynx, and
larynx. The Radiation Therapy Oncology Group (RTOG) 91-11
trial, coordinated by Forastiere et al. was designed to compare
the rates of larynx preservation between two chemoradiotherapy
regimens (with induction or concurrent chemotherapy) and
radiotherapy alone. Adelstein et al. (4) demonstrated a clear
improvement of overall survival, the primary endpoint of the
study (median: from 12.6 to 19.1 months, 5 year rates: from 14 to
26%). In the RTOG 91-11 trial, concurrent chemoradiation with
3 weekly cisplatin emerged as the optimal approach for larynx
preservation, locoregional and distant controls, and disease-free
survival. However, these benefits did not translate into overall
survival advantage with 5 year rates being almost identical across
all three treatment arms (about 55%). What is more, results
of an updated publication after a median follow-up of 10.8
years caused a stir in the oncology community, suggesting a
worse outcome in the concomitant chemoradiation treatment
arm compared with the sequential treatment arm (p = 0.08)
(16). Being attributed to an increase of deaths from non-
cancer related causes probably due to unrecognized late toxicity,
the correct interpretation is still a matter of debate. In this
respect, it should be mentioned that RTOG 91-11 included
only patients with glottic and supraglottic larynx cancer, in
contrast to about 10% of such cases in the Intergroup study
population. Therefore, subsite-specific impact on the results
cannot be excluded.
In the post-operative setting, the RTOG 9501 and the
European Organization for Research and Treatment of Cancer
(EORTC) 22931 trials enrolled 793 patients with high-risk
features in the pathology specimens between 1994 and 2000
(6, 7). The primary objectives were locoregional control and
progression-free survival, respectively. In both trials, the addition
of cisplatin to radiotherapy was associated with a significant
enhancement of 5 year locoregional control and disease- or
progression-free survival, but the prolongation of overall survival
reached statistical significance only in EORTC 22931, being 53%
vs. 40% (hazard ration [HR] 0.70, 95% confidence interval [CI]:
0.52–0.95, p = 0.02) at 5 years. In this context, special attention
should be paid to patient selection criteria. An exploratory
pooled analysis implied that a significant advantage of combined
modality treatment was limited to patients with extracapsular
spread and/or positive surgical margins. Importantly, the EORTC
inclusion criteria definedmicroscopically involvedmargins as the
presence of tumor at 5mm or less, while RTOG 9501 did not
allow such tolerance. Hence, it could be speculated to what extent
this difference influenced the outcomes, above all its impact on
overall survival. In any case, patients with close margins should
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TABLE 1 | Grading of the level of clinical evidence and strength
of recommendation for clinical practice according to the ESMO consensus
guidelines (3).
Level of evidence
I ≥1 large well-conducted randomized control trial or
meta-analyses of such trials
II Randomized control trials with a suspicion of bias or
meta-analyses of such trials
III Prospective cohort studies
IV Retrospective cohort studies or case-control studies






D Generally not recommended
E Never recommended
be considered for adjuvant chemoradiotherapy. Of note, systemic
treatment had no meaningful impact on distant control in these
two trials, with rates varying between 80 and 75% irrespective of
treatment cohort in the adjuvant, but also definitive settings.
Of further evidence has been the individual patient-based
meta-analysis of 87 randomized trials, performed between 1965
and 2000 (17). This meta-analysis demonstrated that adding
chemotherapy to locoregional treatment in locally advanced
SCCHN was associated with an absolute survival advantage of
4.5% at 5 years (p < 0.0001). The conclusions on this benefit
did not differ significantly between post-operative radiotherapy
and definitive curative radiotherapy and with using either
conventional or altered fractionation. However, chemotherapy
protocols varied largely in this meta-analysis in that different
drugs and different dose levels were applied. No preference
for poly-chemotherapy including platin or 5-fluorouracil over
mono-chemotherapy with cisplatin or vice-versa was noted.
Single agent cisplatin appeared, therefore, to be one of the
standard treatments in combination with radiotherapy. Most of
the randomized trials in the analysis used a dose of cisplatin of
100 mg/m2 three times throughout the course of radiotherapy
(cumulative dose of 300 mg/m2), and this came forward as the
preferred and recommended option.
Two further variables remain to be addressed, i.e., toxicity
and compliance. Adding cisplatin to radiotherapy was found
to be associated with an increase in acute adverse events, both
in terms of toxicity related primarily to the systemic treatment
(gastrointestinal, hematological, neurological, and renal side
effects) and toxicity owing mainly to radiotherapy (mucositis,
dysphagia, and skin adverse events). Data on ototoxicity were
not available. As an example, with the addition of high-dose
cisplatin, the rate of severe acute mucositis almost doubled in
EORTC 22931 (from 21 to 41%) and more than one third
of patients developed severe acute dysphagia in RTOG 91-11.
Unfortunately, in general, late toxicity reporting often suffers
from inaccuracy and inconsistency (2). With that in mind, the
cumulative incidence of late toxicity ranged between 20 and
40%, without a statistical correlation with the systemic treatment
(6, 7, 16, 18). It was not surprising that the high rate of acute
side effects came at the cost of decreased compliance. In fact,
the proportion of patients who could receive all planned cycles
of chemotherapy was between 61 and 85%.
DECISION-MAKING PROCESS
The cisplatin-based concurrent chemoradiation protocol
presented above is generally accepted as the reference for the
definitive non-surgical and post-operative approaches in selected
patients with locoregionally advanced SCCHN. At the same
time, the efficacy is far from being satisfactory and toxicity is
one of the major drawbacks. Nevertheless, the four randomized
trials established level I evidence for its use supported by the
individual patient-based meta-analysis, and no other regimen
has proven to outperform this. The decision-making process gets
complicated in the presence of patient-related characteristics
hindering the employment of cisplatin. In their 2016 seminal
work, Ahn et al. (largely opinion leaders from the Asia-Pacific
region) summarized criteria for absolute contraindications
and high-risk cases (19). Subsequently, these criteria were
adopted for the purpose of the present work as absolute and
relative contraindications. The original Ahns’ criteria did not
differentiate between palliative and curative settings. Herein, we
focus on locally advanced disease where the addition of 3 weekly
high-dose cisplatin to radiotherapy may save further patients’
lives, and the absolute overall survival benefit at 5 years may
be even higher than 10% (17). In this respect, the following
modifications were made (Table 2).
First, the age limit of 70 years (calendar age) was removed
because fit elderly individuals receiving full-dose treatment
were shown to derive the same magnitude of clinical benefit
as their younger counterparts (20). Thus, where applicable,
our decisions should implement geriatric screening tools and
if necessary complex geriatric assessment (21). Frailty as a
surrogate marker for biological age represents a crucial factor
in decision making related to older cancer patients. About
10% of the general senior population are expected to be frail.
However, in the context of an oncologic disease, this proportion
rises to over one half, comprising also vulnerable individuals,
with not more than one third being fit. According to recently
published clinical recommendations for systemic therapy of head
and neck cancer in the elderly, fit patients should primarily be
considered for high-dose 3 weekly cisplatin with curative intent,
while treatment in those who are frail will rather consist of
palliative measures such as palliative irradiation and/or palliative
surgical interventions (e.g., tracheostomy, gastrostomy). In the
intermediate group characterized by vulnerability, management
follows the recommendations pertinent to the intermediate
group with relative contraindications to high-dose cisplatin as
explained further in this paper (22).
Next, pre-existing hearing impairment grade II was moved
from absolute to relative contraindications. This condition
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TABLE 2 | Absolute and relative contraindications to cisplatin in definitive or
post-operative treatment of locally advanced head and neck cancer, modified







ECOG score = 2 ECOG score ≥ 3
Biological age According to geriatric










Hearing loss or tinnitus grade =
1 or 2a,b
Hearing loss or tinnitus
grade = ≥ 3a





Grade 2a or Child-Pugh score =
Bc













HIV/AIDS CD4 count 200–350/µld CD4 count < 200/µld
Nutritional status Involuntary weight loss ≥ 20% ND
Pregnancy and
lactation











>200 mg/m2 or >3 cycles of
TPF induction
ND





Impaired social and economic
support
ND
aBased on the National Cancer Institute Common Toxicity Criteria version 4.0.
bRepeated audiometry exams may be indicated during the treatment.
cFor hepatic impairment.
dWorld Health Organization definition.
eFetal exposure to radiation, irrespective of the duration of pregnancy, increases the risk
on developing malignancies in childhood and in addition is associated with abortion and
intra-uterine death. Therefore, radiotherapy is preferably postponed until after delivery.
f If a skin test does not rule out cross-reactions among platinum agents.
HIV/AIDS, human immunodeficiency virus infection/acquired immune deficiency
syndrome; ECOG, Eastern Oncology Cooperative Group; TPF, docetaxel, cisplatin,
5-fluorouracil; ND, not defined.
belongs to the class-specific adverse events of cisplatin and can
indeed be accelerated by such treatment. However, according to
two largemeta-analyses of 59 prospective trials, severe ototoxicity
has not been common even with high cumulative doses of
cisplatin, and the risk-benefit ratio on an individual patient basis
can ultimately favor the standard, high-dose treatment (23, 24).
Still, periodic audiometry exams might be indicated throughout
the treatment course leading eventually to cisplatin interruption
in some cases. Further modifications relative to the Ahn’s criteria
concerning organ dysfunctions, other comorbid conditions, and
pregnancy are listed in Table 2.
The bottom line is that patient and disease characteristics are
crucial in decisionmaking which should preferably be consensual
within the frame of a multidisciplinary tumor board. To facilitate
this task, we have elaborated a decision tree algorithm separately
for the definitive and post-operative treatment settings available
in Figures 1, 2 together with an overview of studies supporting
the resulting level of evidence and grade of recommendation
provided in the Tables S1, S2.
DEFINITIVE TREATMENT SETTING
No Contraindications to High-Dose
Cisplatin
The standard of care should be pursued whenever patients are
in good general condition with few and/or mild comorbidities
and are willing to adhere to the treatment program [I, A].
Alternatively, two cycles of 100 mg/m2 of cisplatin given in
a 3–4 week interval concomitantly with altered fractionation
radiotherapy may be considered [I, B] (12, 24, 25). On the other
hand, current evidence is insufficient to prioritize weekly low-
dose cisplatin protocols (26). Up to now, three prospective trials
comparing survival outcome with weekly low-dose cisplatin-
based chemoradiotherapy vs. radiotherapy alone have been
published. The first two studies, enrolling a total of 275 patients,
were conducted in the 1980s. Quon et al. chose a relatively low
cumulative dose of cisplatin (7× 20 mg/m2) being very probably
responsible for the disappointing results. Median overall survival
was even numerically worse in the combined modality arm
(11.8 months vs. 13.3 months) (27). Sharma et al. doubled
the target cumulative dose (7 × 40 mg/m2) leading apparently
to better outcomes with a significant separation of overall
survival curves (median: 27 months vs. no reached, p = 0.02).
Nevertheless, the median follow-up period did not exceed 2
years and no information on late toxicity was provided (28).
The third prospective study, a three-arm trial comparing two
radiotherapy fractionation schedules with chemoradiation using
up to 8 cycles of 30 mg/m2 cisplatin, was underpowered and had
to be terminated prematurely due to poor accrual (199 out of
750 patients planned). The small improvement in locoregional
control (p = 0.049) did not translate into significant overall
survival improvement and the difference was only numerical (5
year rates: 56% vs. 36%) (29). Other prospective and retrospective
trials exploring the weekly schedule are available but the data
have been conflicting [II, C] (23). For further information
regarding a comparison between the weekly and 3 weekly
regimen please see below in a separate chapter.
Finally, retrospective observations in patients intended
to receive three cycles of high-dose cisplatin suggest that
a cumulative dose of 200 mg/m2 produces an adequate
anti-tumor effect in terms of overall survival, especially in
the prognostically favorable low-risk group of HPV positive
oropharyngeal cancer, with higher doses possibly further
improving locoregional control (11, 25, 30–32). At present, it
is unclear whether dose escalation up to 300 mg/m2 brings
additional survival advantage or whether this is offset by
excessive toxicity responsible for an increase in non-cancer
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FIGURE 1 | Systemic treatment recommendations for definitive chemoradiotherapy. *Particularly in human papillomavirus positive low risk or intermediate risk
oropharyngeal cancer. RT, radiotherapy; HPV+ OPC, human papillomavirus positive oropharyngeal cancer.
related deaths. Similarly, it remains unknown whether the
progressively extending survival associated with 10 mg/m2
cisplatin increments in a range between 140 and 270 mg/m2, as
demonstrated in a model based on 6 phase III trials, is due to
the higher dose itself or to healthier patients better tolerating
additional cisplatin delivery (33). Thus, even if two doses
of 100 mg/m2 cisplatin given concurrently with conventional
fractionation may be considered by some experts sufficient
in the context of drug exposition [IV, C], clinicians should
always ensure maximal comfort and supportive care for their




Owing to the high prevalence of comorbid conditions in patients
with head and neck cancer, many cases fall into this category (34).
Here, more than in any of the two alternative clinical scenarios,
physicians have to rely on local medical expertise including
multidisciplinary tumor board meetings with an emphasis on
patient engagement and shared decision making. Consequently,
some practitioners opt for the standard of care, while others
consider treatment plans recommended in the case of absolute
contraindications to cisplatin (see below) [V, C]. Under such
circumstances, lowering the peak concentration of cisplatin, as
an important determinant for acute toxicity (nausea, vomiting,
transaminase elevations, ototoxicity, serum creatinine increase),
by either prolonging the infusion time (e.g., for 24 h) or reducing
the single dose (e.g., weekly or daily administration or the 3
weekly schedule with a reduced dose) is justifiable as well (19, 35–
38) [V, C]. If preference is given to weekly cisplatin, single doses
of 40 mg/m2 are recommended to ensure that the majority of
patients receive a cumulative dose of at least 200 mg/m2 (28).
The latter proved difficult to be attained with lower single doses,
and this could negatively impact on survival (27, 29). A split
administration of 4× 25 mg/m2 on 4 consecutive days instead of
the standard 100 mg/m2 infusion is currently under investigation
in the GORTEC 2015-02 trial.
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FIGURE 2 | Systemic treatment recommendations for adjuvant (post-operative) chemoradiotherapy. RT, radiotherapy.
Absolute Contraindications to Cisplatin
This situation precludes both high-dose and low-dose cisplatin
regimens. Combining carboplatin 70 mg/m2 and fluorouracil
600 mg/m2 daily for 4 days three times every 3 weeks, the
Groupe d’Oncologie Radiothérapie Tête Et Cou (GORTEC)
regimen was explored in two large randomized trials. Between
1994 and 1997, the GORTEC 94-01 trial randomly allocated 226
oropharyngeal cancer patients to receive either carboplatin/5-
fluorouracil chemotherapy with conventionally fractionated
radiotherapy or radiotherapy alone. The combined modality
arm managed to significantly enhance overall survival and this
benefit was maintained even after a median follow-up of 5.5
years (5 year rates: 22.4% vs. 15.8%) (39, 40). The GORTEC 99-
02 recruited 840 patients between 2000 and 2007, distributing
them evenly between conventional chemoradiotherapy with the
same carboplatin/5-fluorouracil regimen as described above,
accelerated radiotherapy with a slightly modified systemic
treatment, and very accelerated radiotherapy alone. Compared
with the latter approach, conventional chemoradiotherapy
induced superior 3 year PFS (37.6% vs. 32.2%; HR 0.82,
95% CI 0.67–0.99, p = 0.041) and overall survival (42.6% vs.
36.5%; HR 0.81, 95% CI 0.67–0.99, p = 0.04), while the use
of accelerated radiation did not provide any benefit in this
trial. Importantly, giving all three cycles vs. less amount of
chemotherapy seemed to generate better survival and distant
control, and this could not be compensated by acceleration
(41, 42). In both GORTEC 94-01 and GORTEC 99-02, the acute
toxicity was the major downside of this type of conventional
Frontiers in Oncology | www.frontiersin.org 6 June 2019 | Volume 9 | Article 464
Szturz et al. Recommendations for Chemoradiation
chemoradiotherapy. The rate of severe acute mucositis of about
70% was at the limit of clinical acceptance. In GORTEC 94-01, it
almost doubled compared with the standard arm (71% vs. 39%).
In summary, patients with a history of neurological, hearing,
or renal comorbidities as the sole factors precluding cisplatin
administration should be primarily considered for carboplatin/5-
fluorouracil doublet [I, B].
Cetuximab is an immunoglobulin G1 chimeric monoclonal
antibody against epidermal growth factor receptor (EGFR) and
the only approved targeted agent in locoregionally advanced
SCCHN. It is usually administered at an initial dose of 400
mg/m2 followed by weekly doses of 250 mg/m2. Serving as a
possible alternative to platinum derivatives, the IMCL-9815 trial
showed survival advantage with the addition of cetuximab to
radiotherapy alone, primarily integrating altered fractionation
and excluding oral cavity primaries (43). However, as suggested
by several retrospective observations and recently confirmed by
the De-ESCALaTE and RTOG 1016 trials, bioradiation with
cetuximab should not be prioritized over the conventionally or
altered fractionation cisplatin-based chemoradiation either in
terms of efficacy or in terms of acute and late toxicity [II, B]
(11, 12, 44–46). A similar conclusion has recently been suggested
for the anti-tumor activity of the carboplatin/5-fluorouracil (vs.
cetuximab) in patients who were not eligible for high-dose
cisplatin, based on GORTEC 2007-01, showing superiority of
this regimen plus cetuximab vs. cetuximab alone when combined
with radiation (47). Moreover, since the publication of De-
ESCALaTE and RTOG 1016, the recommendation for cetuximab
as an adjunct to definitive radiotherapy has been weaker
in patients with HPV-positive oropharyngeal cancer where it
remains optional in the case of a contraindication for platinum-
based chemotherapy [I, C]. In this situation, hyperfractionated
radiotherapy alone might be a reasonable choice also (please
see below).
Supported by limited scientific evidence, many practicing
oncologist have been using single agent carboplatin as a less toxic
substitute for cisplatin in these circumstances. Between 1988 and
1991, Jeremic et al. tested conventional radiotherapy (arm I) with
or without daily administration of cisplatin (6 mg/m2, arm II) or
carboplatin (25 mg/m2, arm III) (48). Fountzilas et al. utilized
a similar three-arm design but with high-dose cisplatin (100
mg/m2) or carboplatin (area under the curve 7) administered
every 3 weeks for a total of three infusions (49). In both
studies, carboplatin had a significantly positive impact on overall
survival with an acceptable toxicity profile most frequently
in the form of bone marrow suppression. Nonetheless, the
results should be interpreted with caution in view of the clearly
insufficient number of patients treated with carboplatin in each
of these trials (53 and 38, respectively) and its differing dose. Of
note, according to the previously mentioned individual patient-
based meta-analysis, only concomitant monochemotherapy with
cisplatin or polychemotherapy including a platinum derivate or
5-fluorouracil gave a survival advantage when combined with
radiotherapy, and this was not the case when carboplatin alone
was used alone as a radiosensitizer [II, C] (17).
In selected cases where patient-related factors impede
systemic treatment, altered fractionation radiotherapy alone
should be pursued. The greatest survival gain can be achieved
by hyperfractionation, especially in limited nodal disease (N0
and N1). This came forward in a large meta-analysis of 15
randomized trials comparing conventional radiotherapy with
altered fractionation schedules in definitive treatment of non-
metastatic SCCHN [I, B] (50). A recently published update
corroborated its conclusions (51).
POST-OPERATIVE TREATMENT SETTING
No or Only Relative Contraindications to
High-Dose Cisplatin
With the exception of altered fractionation radiotherapy which
should preferably not be delivered in the post-operative setting
and the fact that data supporting a cumulative dose of 200
mg/m2 cisplatin in combination with conventional fractionation
are extrapolated from the definitive setting [V, C], the remaining
recommendations are equivalent to those pertinent to definitive
treatment intent (52). Only one small randomized trial explored
the outcome of adding weekly cisplatin to conventional
radiotherapy in a sample of 88 participants. The statistically
significant improvement of 5 year overall survival (13% vs. 36%),
disease-free survival (23% vs. 45%), and locoregional control
(55% vs. 70%) was accompanied by an increase in severe acute
adverse events (16% vs. 41%). Of note, the used single (50mg/m2)
and cumulative (350–450 mg/m2) cisplatin doses exceeded those
employed in current protocols, limiting thus the applicability of
this weekly regimen in daily practice (53, 54). Data from other
prospective and retrospective studies do not permit substituting
the 3 weekly for a weekly schedule on a routine basis (23). For
more on this subject, please refer to a separate chapter below.
Absolute Contraindications to Cisplatin
In case the risk/benefit ratio strongly discourages from exposing
patients to cisplatin, there is no adequate systemic replacement.
In this context, patients with a high risk for recurrence should
routinely receive conventional radiotherapy alone despite a
paucity of randomized trials of post-operative radiotherapy
vs. observation, originating from the fact that the concept
of adjuvant therapy developed empirically [III, B] (55).
Nevertheless, addressing the clinical need to potentiate treatment
outcomes above all in patients in good clinical condition without
other contraindications, several systemic agents have been
recommended in combination with conventional radiotherapy
in this setting. In the randomized RTOG 0234 phase II trial,
238 patients treated with post-operative radiotherapy were evenly
divided into the following two arms, cetuximab with weekly
cisplatin 30 mg/m2 or cetuximab with weekly docetaxel 15
mg/m2. With a median follow-up of 4.4 years, the latter regimen
augmented overall survival relative to historical controls from
the RTOG 9501 trial (2 year rates: 79% vs. 65%) with a 54%
rate of severe acute mucositis [III, B] (56). Although some
advantage has been suggested with the use of paclitaxel in
definitive chemoradiation de-escalation trials in HPV-positive
oropharyngeal cancer, this has not been tested in the post-
operative setting (57, 58).
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On the contrary, for single-agent cetuximab as an adjunct
to post-operative radiotherapy no prospective evidence exists,
and a recently published report on a small series of patients
discouraged from its use here (59). Therefore, with the additional
negative results of cetuximab/radiation in comparison with
cisplatin/radiation in the definitive setting (see earlier) we do
not recommend this approach [V, D]. Similarly, carboplatin/5-
fluorouracil doublet has never been tested prospectively after
curative resection. Nevertheless, it has been generally accepted
as an adequate surrogate for high-dose cisplatin concurrent
with definitive radiotherapy, and we assume comparable
activity when extrapolated to the adjuvant setting [V, B].
However, for single-agent carboplatin, the rationale is weak
at present. The only randomized trial in mucosal SCCHN
was closed prematurely due to slow accrual and did not
demonstrate any benefit with the addition of weekly carboplatin
to adjuvant radiotherapy [II, D] (60). This is in line with
another negative phase III trial performed in 321 patients
with cutaneous SCCHN. The Trans-Tasman Radiation Oncology
Group (TROG) 05.01 study provided high-quality data with
a median follow-up of 60 months showing that potentiation
by weekly low-dose carboplatin had no effect on survival or
toxicity (61).
WEEKLY VS. 3 WEEKLY CISPLATIN
As alluded to above, 3 weekly high-dose cisplatin delivered
concurrently with external beam radiotherapy remains the
standard of care. This is in line with the results of a composite
meta-analysis of 59 prospective trials enrolling altogether
5,582 patients (23, 24, 26). Although the weekly schedule
produced less severe acute adverse events than three cycles
of the standard regimen when combined with conventionally
fractionated radiotherapy, no benefit could be observed in
survival and late toxicity analyses. Of note, only two thirds
of patients allocated to the high-dose arm could receive all
three cycles (23). On the other hand, altered fractionation
was associated with a significant advantage of two high-dose
cisplatin cycles not only in terms of overall survival but in
acute and late side effects. Here, the compliance with the
standard regimen surpassed 90% (24). Moreover, in patients
treated with adjuvant intent, two prospective trials comparing
weekly vs. 3 weekly cisplatin are available. The first has been
reported by Tsan et al. Among 55 randomly assigned patients
followed for a median of 12 months, the 3 weekly regimen
produced less acute toxicity, particularly severe mucositis, than
weekly 40 mg/m2 cisplatin and proved also superiority in
terms of reaching cumulative doses of at least 200 mg/m2 (62).
Another proof against the routine use of weekly cisplatin was
recently furnished by a single-center phase III trial from the
Tata Memorial Cancer Centre in Mumbay, India, comparing
weekly 30 mg/m2 vs. 3 weekly 100 mg/m2 cisplatin. Non-
inferiority of the low-dose regimen could not be confirmed.
The standard, high-dose group, showed significant gain in
locoregional control, the primary objective (73.1% vs. 58.5%
at 2 years, p = 0.014), albeit at the cost of an increased
incidence of acute (84.6% vs. 71.6%, p = 0.006), but not late side
effects (63).
In summary, the enhanced short-term tolerance of weekly
cisplatin (i.e., less acute nausea, vomiting, transaminase
elevations, ototoxicity, serum creatinine increase, and
myelotoxicity) may be outweighed by compromised survival and
a lack of improvement in late toxicity.
CONCLUSIONS
With the advent of novel targeted drugs, particularly
immunotherapy, the landscape of head and neck cancer
management has been undergoing profound changes affecting
the recurrent and/or metastatic setting in the first place.
In locoregionally advanced disease, the limited efficacy and
unfavorable safety profile of the standard cisplatin-based
chemoradiation has prompted many attempts at improving
or even substituting this regimen. Now, 15 years after the
publication of the four seminal articles, there is finally
some reason for optimism. The activity of the immune
checkpoint inhibitors nivolumab and pembrolizumab has
been demonstrated in at least three large phase III trials in
recurrent/metastatic SCCHN and in 2019, the efficacy results of
the first studies performed in the locoregionally advanced disease
setting will be presented as well, including the PembroRad
trial (NCT02707588) randomizing patients between definitive
radiotherapy with pembrolizumab or cetuximab and the RTOG
3504 trial (NCT02764593) exploring different combinations of
definitive radiotherapy, nivolumab, cisplatin, and cetuximab.
Recommendations presented in this review paper should
not be understood as a dogmatic system of rules but rather a
frame to guide clinical decision making in which we underscore
an individual approach allowing for patient- and disease-
related factors. The relevance of these instructions should
pertain at least for some time even in the era of modern
immunotherapy because the availability and accessibility of
immunomodulating antibodies will unfortunately be restricted in
many countries worldwide. In this situation, cisplatin will retain
its significance and continue to represent a cost-effective and
feasible modality saving patients’ lives.
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